Jeremy Koppel, MD
Psychiatry · Glen Oaks, NYNPI 1861562209
Payments from drug & device makers
What this record shows
This record is dominated by grants: $61,309 of the $61,309 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Acadia Pharmaceuticals Inc. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2 payments — averaging $30,655 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$61K
Across 18 payments — averaging $7013.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$57K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$50K
- Avanir Pharmaceuticals, Inc.$20K
What the payments were for
- Grants$61,309100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 2 | $61,309 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$61,309
How this compares
$61,309 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 52 | $6,400 |
| Quetiapine Fumarate | 28 | $1,024 |
| Clonazepam | 48 | $932 |
| Olanzapine | 27 | $715 |
| Mirtazapine | 28 | $636 |
| Fluphenazine Decanoate | 11 | $569 |
| Sertraline Hcl | 35 | $445 |
| Risperidone | 66 | $424 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $377 |
| Escitalopram Oxalate | 38 | $349 |
| Trazodone Hcl | 20 | $141 |
| Lorazepam | 25 | $116 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glen Oaks
- Christoph CorrellGlen Oaks$1.5M
- John KaneGlen Oaks$817K
- Youssef HassounGlen Oaks$233K
- Jose Rubio-LorenteGlen Oaks$106K
- Delbert RobinsonGlen Oaks$83K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Manish ZinzuvadiaNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.